Sana Biotechnology (NASDAQ:SANA) versus Monte Rosa Therapeutics (NASDAQ:GLUE) Financial Survey

Monte Rosa Therapeutics (NASDAQ:GLUE) and Sana Biotechnology (NASDAQ:SANA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership and dividends.

Volatility & Risk

Monte Rosa Therapeutics has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500. Comparatively, Sana Biotechnology has a beta of 2.16, indicating that its stock price is 116% more volatile than the S&P 500.

Earnings & Valuation

This table compares Monte Rosa Therapeutics and Sana Biotechnology”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	$28.73 million	39.74	-$38.63 million	($1.76)	-7.60
Sana Biotechnology	N/A	N/A	-$244.17 million	($0.76)	-5.17

Monte Rosa Therapeutics has higher revenue and earnings than Sana Biotechnology. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Monte Rosa Therapeutics and Sana Biotechnology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-560.85%	-43.31%	-27.59%
Sana Biotechnology	N/A	-103.02%	-39.16%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Monte Rosa Therapeutics and Sana Biotechnology, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	1	1	6	1	2.78
Sana Biotechnology	1	1	7	1	2.80

Monte Rosa Therapeutics presently has a consensus price target of $28.50, suggesting a potential upside of 113.00%. Sana Biotechnology has a consensus price target of $9.33, suggesting a potential upside of 137.49%. Given Sana Biotechnology’s stronger consensus rating and higher probable upside, analysts plainly believe Sana Biotechnology is more favorable than Monte Rosa Therapeutics.

Institutional and Insider Ownership

80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are owned by institutional investors. 6.4% of Monte Rosa Therapeutics shares are owned by insiders. Comparatively, 25.4% of Sana Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Sana Biotechnology beats Monte Rosa Therapeutics on 9 of the 13 factors compared between the two stocks.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

About Sana Biotechnology

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company’s product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin’s lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam’s proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.